Molecular action of lenalidomide in lymphocytes and hematologic malignancies

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  McDaniel, Jessica M ^a,b   Pinilla Ibarz, Javier ^b   Epling Burnette, P K ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; PNEUMOCOCCUS VACCINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SPECIFICITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84864917125     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/513702     Document Type: Review

References (86)

1. Iyer C. G., Languillon J., Ramanujam K., Tarabini-Castellani G., De las Aguas J. T., Bechelli L. M., Uemura K., Martinez Dominguez V., Sundaresan T., WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients Bulletin of the World Health Organization 1971 45 6 719 732
2. Sheskin J., The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide International Journal of Dermatology 1980 19 6 318 322 (Pubitemid 11233278)
3. Gutierrez-Rodriguez O., Thalidomide: a promising new treatment for rheumatoid arthritis Arthritis and Rheumatism 1984 27 10 1118 1121 (Pubitemid 14022225)
4. Atra E., Sato E. I., Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide Clinical and Experimental Rheumatology 1993 11 5 487 493 (Pubitemid 23328811)
5. Hamza M. H., Treatment of Behcet's disease with thalidomide Clinical Rheumatology 1986 5 3 365 371
6. Muller G. W., Corral L. G., Shire M. G., Wang H., Moreira A., Kaplan G., Stirling D. I., Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity Journal of Medicinal Chemistry 1996 39 17 3238 3240 (Pubitemid 26322847)
7. Kotla V., Goel S., Nischal S., Heuck C., Vivek K., Das B., Verma A., Mechanism of action of lenalidomide in hematological malignancies Journal of Hematology and Oncology 2009 2, article 36
8. Saloura V., Grivas P. D., Lenalidomide: a synthetic compound with an evolving role in cancer management Hematology 2010 15 5 318 331
9. Carballido E., Veliz M., Komrokji R., Pinilla-Ibarz J., Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia Cancer Control 2012 19 1 54 67
10. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape Nature Immunology 2002 3 11 991 998 (Pubitemid 35363648)
11. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN, and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 2001 410 6832 1107 1111 (Pubitemid 32391043)
12. Haslett P. A. J., Corral L. G., Albert M., Kaplan G., Thalidomide costimulates primary human t lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset Journal of Experimental Medicine 1998 187 11 1885 1892 (Pubitemid 28262451)
13. List A., Kurtin S., Roe D. J., Buresh A., Mahadevan D., Fuchs D., Rimsza L., Heaton R., Knight R., Zeldis J. B., Efficacy of lenalidomide in myelodysplastic syndromes The New England Journal of Medicine 2005 352 6 549 557 (Pubitemid 40204668)
14. Linsley P. S., Greene J. L., Brady W., Bajorath J., Ledbetter J. A., Peach R., Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors Immunity 1994 1 9 793 801
15. Bretscher P. A., A two-step, two-signal model for the primary activation of precursor helper T cells Proceedings of the National Academy of Sciences of the United States of America 1999 96 1 185 190 (Pubitemid 29036074)
16. Keene J. A., Forman J., Helper activity is required for the in vivo generation of cytotoxic T lymphocytes Journal of Experimental Medicine 1982 155 3 768 782 (Pubitemid 12187851)
17. Mustelin T., Taskén K., Positive and negative regulation of T-cell activation through kinases and phosphatases Biochemical Journal 2003 371, part 1 15 27 (Pubitemid 36458075)
18. Williams M. A., Tyznik A. J., Bevan M. J., Interleukin-2 signals during priming are required for secondary expansion of CD8 + memory T cells Nature 2006 441 7095 890 893
19. Nakayama T., Yamashita M., The TCR-mediated signaling pathways that control the direction of helper T cell differentiation Seminars in Immunology 2010 22 5 303 309
20. LeBlanc R., Hideshima T., Catley L. P., Shringarpure R., Burger R., Mitsiades N., Mitsiades C., Cheema P., Chauhan D., Richardson P. G., Anderson K. C., Munshi N. C., Immunomodulatory drug costimulates T cells via the B7-CD28 pathway Blood 2004 103 5 1787 1790 (Pubitemid 38268973)
21. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., Kumar S., Chauhan D., Treon S. P., Richardson P., Anderson K. C., Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application British Journal of Haematology 2005 128 2 192 203
22. Payvandi F., Wu L., Naziruddin S. D., Haley M., Parton A., Schafer P. H., Chen R. S., Muller G. W., Hughes C. C. W., Stirling D. I., Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC- activation and enhancing the DNA-binding activity of AP-1 but not NF- B, OCT-1, or NF-AT Journal of Interferon and Cytokine Research 2005 25 10 604 616 (Pubitemid 41507816)
23. Schafer P. H., Gandhi A. K., Loveland M. A., Chen R. S., Man H. W., Schnetkamp P. P. M., Wolbring G., Govinda S., Corral L. G., Payvandi F., Muller G. W., Stirling D. I., Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs Journal of Pharmacology and Experimental Therapeutics 2003 305 3 1222 1232 (Pubitemid 36618002)
24. Grgn G., Calabrese E., Soydan E., Hideshima T., Perrone G., Bandi M., Cirstea D., Santo L., Hu Y., Tai Y. T., Nahar S., Mimura N., Fabre C., Raje N., Munshi N., Richardson P., Anderson K. C., Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma Blood 2010 116 17 3227 3237
25. Smyth M. J., Godfrey D. I., Trapani J. A., A fresh look at tumor immunosurveillance and immunotherapy Nature Immunology 2001 2 4 293 299 (Pubitemid 33706339)
26. Galustian C., Meyer B., Labarthe M. C., Dredge K., Klaschka D., Henry J., Todryk S., Chen R., Muller G., Stirling D., Schafer P., Bartlett J. B., Dalgleish A. G., The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunology, Immunotherapy 2009 58 7 1033 1045
27. Giannopoulos K., Schmitt M., Wasiuk P., Chen J., Bojarska-Junak A., Kowal M., Roliski J., Dmoszyska A., The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide Leukemia 2008 22 1 222 224
28. McDaniel J. M., Zou J. X., Fulp W., Chen D.-T., List A. F., Epling-Burnette P. K., Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation Leukemia 2012 26 6 1425 1429
29. Noonan K., Rudraraju L., Ferguson A., Emerling A., Pasetti M. F., Huff C. A., Borrello I., Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses Clinical Cancer Research 2012 18 5 1426 1434
30. Scrivener S., Goddard R. V., Kaminski E. R., Prentice A. G., Abnormal T-cell function in B-cell chronic lymphocytic leukaemia Leukemia and Lymphoma 2003 44 3 383 389 (Pubitemid 36118829)
31. Kiaii S., Choudhury A., Mozaffari F., Kimby E., sterborg A., Mellstedt H., Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease Medical Oncology 2005 22 3 291 302 (Pubitemid 41176325)
32. Ramsay A. G., Clear A. J., Fatah R., Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide. Blood. In press
33. Lee B. N., Gao H., Cohen E. N., Badoux X., Wierda W. G., Estrov Z., Faderl S. H., Keating M. J., Ferrajoli A., Reuben J. M., Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia Cancer 2011 117 17 3999 4008
34. Neuber B., Herth I., Tolliver C., Schoenland S., Hegenbart U., Hose D., Witzens-Harig M., Ho A. D., Goldschmidt H., Klein B., Hundemer M., Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma The Journal of Immunology 2011 187 2 1047 1056
35. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H., Identification of a primary target of thalidomide teratogenicity Science 2010 327 5971 1345 1350
36. Zhu Y. X., Braggio E., Shi C.-X., Bruins L. A., Schmidt J. E., Van Wier S., Chang X.-B., Bjorklund C. C., Fonseca R., Bergsagel P. L., Orlowski R. Z., Stewart A. K., Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide Blood 2011 118 18 4771 4779
37. Ren S., Xu C., Cui Z., Yu Y., Xu W., Wang F., Lu J., Wei M., Lu X., Gao X., Liang Y., Mao J. H., Sun Y., Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. Journal of Molecular Medicine. In press
38. Wei S., Chen X., McGraw K., Zhang L., Komrokji R., Clark J., Caceres G., Billingsley D., Sokol L., Lancet J., Fortenbery N., Zhou J., Eksioglu E. A., Sallman D., Wang H., Epling-Burnette P. K., Djeu J., Sekeres M., Maciejewski J. P., List A., Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. In press
39. Awan F. T., Johnson A. J., Lapalombella R., Hu W., Lucas M., Fischer B., Byrd J. C., Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia Leukemia and Lymphoma 2010 51 1 27 38
40. Chanan-Khan A., Miller K. C., Musial L., Lawrence D., Padmanabhan S., Takeshita K., Porter C. W., Goodrich D. W., Bernstein Z. P., Wallace P., Spaner D., Mohr A., Byrne C., Hernandez-Ilizaliturri F., Chrystal C., Starostik P., Czuczman M. S., Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study Journal of Clinical Oncology 2006 24 34 5343 5349 (Pubitemid 46623164)
41. Chen C. I., Bergsagel P. L., Paul H., Xu W., Lau A., Dave N., Kukreti V., Wei E., Leung-Hagesteijn C., Li Z. H., Brandwein J., Pantoja M., Johnston J., Gibson S., Hernandez T., Spaner D., Trudel S., Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia Journal of Clinical Oncology 2011 29 9 1175 1181
42. Ferrajoli A., Lee B. N., Schlette E. J., O'Brien S. M., Gao H., Wen S., Wierda W. G., Estrov Z., Faderl S., Cohen E. N., Li C., Reuben J. M., Keating M. J., Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia Blood 2008 111 11 5291 5297
43. Chanan-Khan A., Porter C. W., Immunomodulating drugs for chronic lymphocytic leukaemia The Lancet Oncology 2006 7 6 480 488 (Pubitemid 43796153)
44. Ramsay A. G., Johnson A. J., Lee A. M., Gorgn G., Dieu R. L., Blum W., Byrd J. C., Gribben J. G., Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug The Journal of Clinical Investigation 2008 118 7 2427 2437 (Pubitemid 351949771)
45. Gorgun G., Ramsay A. G., Holderried T. A. W., Zahrieh D., Dieu R. L., Liu F., Quackenbush J., Croce C. M., Gribben J. G., E -TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction Proceedings of the National Academy of Sciences of the United States of America 2009 106 15 6250 6255
46. Ramsay A. G., Clear A. J., Fatah R., Gribben J. G., Lenalidomide repairs suppressed T cell immunological synapse formation in follicular lymphoma Blood 2008 112. Abstract no. 885
47. Chanan-Khan A. A., Chitta K., Ersing N., Paulus A., Masood A., Sher T., Swaika A., Wallace P. K., Mashtare T. L. Jr., Wilding G., Lee K., Czuczman M. S., Borrello I., Bangia N., Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response British Journal of Haematology 2011 155 4 457 467
48. Chanan-Khan A., Miller K. C., Lawrence D., Padmanabhan S., Miller A., Hernandez-Illatazurri F., Czuczman M. S., Wallace P. K., Zeldis J. B., Lee K., Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response Cancer 2011 117 10 2127 2135
49. Dhodapkar M. V., Geller M. D., Chang D. H., Shimizu K., Fujii S. I., Dhodapkar K. M., Krasovsky J., A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma Journal of Experimental Medicine 2003 197 12 1667 1676 (Pubitemid 36745342)
50. Perri R. T., Oken M. M., Kay N. E., Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma Journal of Laboratory and Clinical Medicine 1982 99 4 512 519 (Pubitemid 12086373)
51. Kyle R. A., Rajkumar S. V., Drug therapy: multiple myeloma The New England Journal of Medicine 2004 351 18 1860 1921
52. Breitkreutz I., Raab M. S., Vallet S., Hideshima T., Raje N., Mitsiades C., Chauhan D., Okawa Y., Munshi N. C., Richardson P. G., Anderson K. C., Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma Leukemia 2008 22 10 1925 1932
53. Geitz H., Handt S., Zwingenberger K., Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology 1996 31 2-3 213 221 (Pubitemid 26122649)
54. Lichtenstein A., Tu Y., Fady C., Vescio R., Berenson J., Interleukin-6 inhibits apoptosis of malignant plasma cells Cellular Immunology 1995 162 2 248 255
55. Brown R. D., Pope B., Murray A., Esdale W., Sze D. M., Gibson J., Joy Ho P., Hart D., Joshua D., Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor- 1 and interleukin-10 Blood 2001 98 10 2992 2998
56. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., Fogli M., Ferri E., Cuna G. R. D., Tura S., Baccarani M., Lemoli R. M., Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6 Blood 2002 100 1 230 237 (Pubitemid 35177452)
57. Christensen O., Lupu A., Schmidt S., Condomines M., Belle S., Maier A., Hose D., Neuber B., Moos M., Kleist C., Terness P., Ho A. D., Goldschmidt H., Klein B., Hundemer M., Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24 Journal of Immunotherapy 2009 32 6 613 621
58. Barlozzari T., Reynolds C. W., Herberman R. B., In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats The Journal of Immunology 1983 131 2 1024 1027 (Pubitemid 13079060)
59. Huber V. C., Lynch J. M., Bucher D. J., Le J., Metzger D. W., Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections The Journal of Immunology 2001 166 12 7381 7388 (Pubitemid 32525614)
60. Wai L. E., Garcia J. A., Martinez O. M., Krams S. M., Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells The Journal of Immunology 2011 186 1 222 229
61. Davies F. E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y. T., Lin B., Podar K., Gupta D., Chauhan D., Treon S. P., Richardson P. G., Schlossman R. L., Morgan G. J., Muller G. W., Stirling D. I., Anderson K. C., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 2001 98 1 210 216
62. Zhu D., Corral L. G., Fleming Y. W., Stein B., Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation Cancer Immunology, Immunotherapy 2008 57 12 1849 1859
63. Hsu A. K., Quach H., Tai T., Prince H. M., Harrison S. J., Trapani J. A., Smyth M. J., Neeson P., Ritchie D. S., The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy Blood 2011 117 5 1605 1613
64. Carbone E., Neri P., Mesuraca M., Fulciniti M. T., Otsuki T., Pende D., Groh V., Spies T., Pollio G., Cosman D., Catalano L., Tassone P., Rotoli B., Venuta S., HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells Blood 2005 105 1 251 258 (Pubitemid 40053090)
65. Wu L., Parton A., Lu L., Adams M., Schafer P., Bartlett J. B., Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers Cancer Immunology, Immunotherapy 2011 60 1 61 73
66. Benson D. M. Jr., Bakan C. E., Zhang S., Collins S. M., Liang J., Srivastava S., Hofmeister C. C., Efebera Y., Andre P., Romagne F., Bléry M., Bonnafous C., Zhang J., Clever D., Caligiuri M. A., Farag S. S., IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect Blood 2011 118 24 6387 6391
67. Butte M. J., Keir M. E., Phamduy T. B., Sharpe A. H., Freeman G. J., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 2007 27 1 111 122 (Pubitemid 47089023)
68. Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H., PD-1 and its ligands in tolerance and immunity Annual Review of Immunology 2008 26 677 704 (Pubitemid 351600389)
69. Benson D. M., Bakan C. E., Mishra A., Hofmeister C. C., Efebera Y., Becknell B., Baiocchi R. A., Zhang J., Yu J., Smith M. K., Greenfield C. N., Porcu P., Devine S. M., Rotem-Yehudar R., Lozanski G., Byrd J. C., Caligiuri M. A., The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody Blood 2010 116 13 2286 2294
70. Wu L., Adams M., Carter T., Chen R., Muller G., Stirling D., Schafer P., Bartlett J. B., Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells Clinical Cancer Research 2008 14 14 4650 4657
71. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S., Functions of natural killer cells Nature Immunology 2008 9 5 503 510 (Pubitemid 351560519)
72. Kaufmann H., Raderer M., Whrer S., Pspk A., Bankier A., Zielinski C., Chott A., Drach J., Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood 2004 104 8 2269 2271 (Pubitemid 39331822)
73. Zhang L., Qian Z., Cai Z., Sun L., Wang H., Bartlett J. B., Yi Q., Wang M., Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo American Journal of Hematology 2009 84 9 553 559
74. Fowler MP N. H., Kwak L., Hagemeister F., Fanale M., Fayad L., Pro B., Samaniego F., Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 2009 27, 15s. Abstract no. 8548
75. Veliz SR M., Lancet J. E., Komrokji R. S., Kharfan-Dabaja M. A., Powers J. J., Dubovsky J. A., Tinsley S., Deaver D., Sotomayor E. M., Pinilla-Ibarz J., Phase II study of lenalidomide in combination with rituximab for patients with CD5 + /CD20 + hematologic malignancies who relapse or progress after rituximab: interim analysis Blood 2009 114, article 2376
76. Du J., Yang H., Guo Y., Ding J., Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20 Molecular Immunology 2009 46 11-12 2419 2423
77. Wierda W. G., Padmanabhan S., Chan G. W., Gupta I. V., Lisby S., sterborg A., Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study Blood 2011 118 19 5126 5129
78. Mssner E., Brnker P., Moser S., Pntener U., Schmidt C., Herter S., Grau R., Gerdes C., Nopora A., Van Puijenbroek E., Ferrara C., Sondermann P., Jger C., Strein P., Fertig G., Friess T., Schll C., Bauer S., Dal Porto J., Del Nagro C., Dabbagh K., Dyer M. J. S., Poppema S., Klein C., Umaa P., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity Blood 2010 115 22 4393 4402
79. Robak T., GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies Current Opinion in Investigational Drugs 2009 10 6 588 596
80. Bologna L., Gotti E., Manganini M., Rambaldi A., Intermesoli T., Introna M., Golay J., Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab The Journal of Immunology 2011 186 6 3762 3769
81. Morschhauser F. C. G., Lamy T., Milpied N., Thieblemont C., Tilly H., Weisser M., Birkett J., Salles G., Phase I study of RO5072759 (GA101) in relapsed /refractory CLL 114 ASH Ann Meeting Abstract 2009. Abstract no. 364
82. Sehn AS L. H., Steward D. A., Mangel J., Pisa P., Kothari J., Crump M., A Phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiple relapsed/refractory CD20 + malignant disease 114 ASH Ann Meeting Abstract 2009. Abstract no. 385
83. Badoux X., 'Brien SM O., Wierda W. G., Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a phase II trial Blood (ASH Annual Meeting Abstracts) 2010 116. Abstract no. 2464
84. Lonial S., Vij R., Harousseau J. L., Facon T., Moreau P., Mazumder A., Kaufman J. L., Leleu X., Tsao L. C., Westland C., Singhal A. K., Jagannath S., Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma Journal of Clinical Oncology 2012 30 16 1953 1959
85. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., Pardoll D., Levitsky H., Induction of antigen-specific T cell anergy: an early event in the course of tumor progression Proceedings of the National Academy of Sciences of the United States of America 1998 95 3 1178 1183 (Pubitemid 28124932)
86. Horna P., Sotomayor E. M., Cellular and molecular mechanisms of tumor-induced T-cell tolerance Current Cancer Drug Targets 2007 7 1 41 53 (Pubitemid 46345507)